Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161615 · ClinicalTrials.gov registry record · Phase 3
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder
A Phase 3 study of Bursitis and Acute Tendonitis, sponsored by MEDRx USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT01161615: Completed Phase 3 study of Bursitis and Acute Tendonitis, sponsored by MEDRx USA.
NCT01161615 is a Phase 3 study of Bursitis and Acute Tendonitis that has completed, run by MEDRx USA. The registered enrollment target is 350 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01161615, a Phase 3 study of Bursitis and Acute Tendonitis, has completed, sponsored by MEDRx USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MRX-7EAT
Study Locations (20)
Florida
- - Daytona Beach
- - Fort Lauderdale
- - Gulf Breeze
- - Orlando
- - West Palm Beach
Indiana
- - Avon
- - Fishers
- - Franklin
- - Greenfield
- - Muncie
California
- - Chico
- - Mission Hills
- - Palm Springs
- - San Diego
Colorado
- - Aurora
- - Colorado Springs
- - Denver
Arizona
- - Chandler
- - Phoenix
Arkansas
- - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
What the finished NCT01161615 record still lists
NCT01161615 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Bursitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01161615 names 20 study sites across 6 states, led by Florida, Indiana, California.
Frequently Asked Questions
What is clinical trial NCT01161615 about?
NCT01161615 is a clinical study titled "MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder". A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder.
What is the current status of trial NCT01161615?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2010-07. Estimated completion is 2011-06.
What conditions does trial NCT01161615 study?
This clinical trial studies the following conditions: Bursitis, Acute Tendonitis.
What interventions are being tested in trial NCT01161615?
The interventions under investigation include: Placebo (DRUG), MRX-7EAT (DRUG).
Who is sponsoring clinical trial NCT01161615?
This trial is sponsored by MEDRx USA, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161615 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bursitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01161615's enrollment target sits among peer trials
350 1034th of 2000 higher than 956 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia